<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00132470</url>
  </required_header>
  <id_info>
    <org_study_id>AX200_P2A_1</org_study_id>
    <nct_id>NCT00132470</nct_id>
  </id_info>
  <brief_title>Treatment With AX200 for Acute Ischemic Stroke</brief_title>
  <official_title>AXIS IIa - Treatment With AX200 for Acute Ischemic Stroke</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Axaron Bioscience AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Axaron Bioscience AG</source>
  <brief_summary>
    <textblock>
      The AXIS study is a randomized, double-blind, placebo-controlled, dose-escalating phase IIa
      trial to investigate treatment with AX200 (granulocyte-colony stimulating factor; G-CSF) for
      acute ischemic stroke. The primary objective of the present phase IIa study is to assess the
      safety and tolerability of AX200 compared to placebo in subjects suffering from acute stroke.
      The secondary objective is to assess the effect of AX200 on subject outcome in comparison to
      placebo.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2004</start_date>
  <completion_date>March 2007</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Neurological outcome</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ischemic lesion growth</measure>
  </secondary_outcome>
  <enrollment>42</enrollment>
  <condition>Cerebral Stroke</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AX200 (G-CSF)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Stroke onset within 12 hours prior to start of study agent administration

          -  Ischemic stroke in the middle cerebral artery (MCA) territory confirmed by magnetic
             resonance imaging (MRI)

        Exclusion Criteria:

          -  Time interval since stroke onset impossible to determine

          -  Carotid T-occlusion (magnetic resonance angiography [MRA])

          -  Subarachnoid hemorrhages

          -  Several safety parameters
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wolf-R체diger Sch채bitz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Muenster</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Neurology University of Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurology University of Muenster</name>
      <address>
        <city>Muenster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.sygnis.de/index_eng.html</url>
  </link>
  <reference>
    <citation>Schneider A, Kr체ger C, Steigleder T, Weber D, Pitzer C, Laage R, Aronowski J, Maurer MH, Gassler N, Mier W, Hasselblatt M, Kollmar R, Schwab S, Sommer C, Bach A, Kuhn HG, Sch채bitz WR. The hematopoietic factor G-CSF is a neuronal ligand that counteracts programmed cell death and drives neurogenesis. J Clin Invest. 2005 Aug;115(8):2083-98. Epub 2005 Jul 7.</citation>
    <PMID>16007267</PMID>
  </reference>
  <verification_date>July 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 18, 2005</study_first_submitted>
  <study_first_submitted_qc>August 18, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 22, 2005</study_first_posted>
  <last_update_submitted>July 23, 2007</last_update_submitted>
  <last_update_submitted_qc>July 23, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 25, 2007</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

